AstraZeneca cancer drug Enhertu show encouraging initial results for other tumours
[1/2] AstraZeneca's cancer medicine Enhertu, a drug developed jointly with Japan's Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022. AstraZeneca/Handout via REUTERS
March 6 (Reuters) - (This March 6 story has been refiled to say that Daiichi Sankyo is a co-developer of Enhertu)
AstraZeneca (AZN.L) said on Monday a mid-stage trial of its cancer drug Enhertu, co-developed with Daiichi Sankyo (4568.T), showed positive results across multiple HER2-expressing advanced solid tumours in heavily pre-treated patients.
The ongoing DESTINY-PanTumor02 Phase II trial is assessing the efficacy and safety of Enhertu in patients with locally advanced or metastatic previously treated solid tumours that are not eligible for curative therapy, including cervical, ovarian, pancreatic, and rare cancers.
"Enhertu has already demonstrated its potential to improve outcomes for patients with HER2-targetable breast, gastric and lung cancers, and these positive initial results in other tumour settings with significant unmet need are very encouraging," Cristian Massacesi, AstraZeneca's chief medical officer and oncology chief development officer, said in a statement.
Our Standards: The Thomson Reuters Trust Principles.
